
- Oncology NEWS International Vol 8 No 12
- Volume 8
- Issue 12
First ‘Unconventional Innovations Program’ NCI Grants Awarded
BETHESDA, Md-Researchers at five institutions have received the first contracts awarded by a new National Cancer Institute program intended to develop novel “one-stop” technologies capable of both detecting and destroying tumor cells. The five contracts, each of which is for 3 years, totaled nearly $11.3 million.
BETHESDA, MdResearchers at five institutions have received the first contracts awarded by a new National Cancer Institute program intended to develop novel one-stop technologies capable of both detecting and destroying tumor cells. The five contracts, each of which is for 3 years, totaled nearly $11.3 million.
The Unconventional Innovations Program supports peer-reviewed, high-risk, high-impact ideas that have the potential to revolutionize cancer care. Additional contracts will be let over the next 3 years.
If successful, the research would lay the technological framework for a future in which people at risk for cancer might receive body scans or other non-invasive tests that sense the telltale early chemical features that are unique to developing tumors and eliminate them, the NCI said in announcing the contracts.
Contracts were awarded to:
The University of Michigan, James Baker, MD, principal investigator; $4,427,711 to develop nanoscale devices for detecting and treating cancer.
The University of Pennsylvania, Britton Chance, PhD, principal investigator; $2,005,552 to study an optical technique using near-infrared light to identify precancerous and cancerous tumors.
The University of Alabama at Birmingham, David Curiel, MD, principal investigator; $1,780,510 to study a system to define tumor cell signatures.
The University of California, Davis, N. C. Luhmann, Jr., principal investigator; $1,611,670 to investigate a prototype compact device to produce high-contrast x-rays.
NASAs Ames Research Center, Meyya Meyyapan, PhD, principal investigator; $1,468,957 to study a carbon nanotube-based biosensor and a prototype biosensor catheter.
Articles in this issue
almost 26 years ago
SWOG to Study Docetaxel/Estramustine in Advanced Prostate Canceralmost 26 years ago
US Smoking Rates No Longer Falling, Due to More Young Smokersalmost 26 years ago
Americans Favor Higher Cigarette Tax to Balance the Budgetalmost 26 years ago
Saint Vincents Hospital Opens Comprehensive Cancer Centeralmost 26 years ago
New Breast Biopsy Techniques Allow ‘One-Stop’ Proceduresalmost 26 years ago
Director of NCI Mentioned as a Candidate to Head NIHalmost 26 years ago
Challenges in Designing Chemoprevention Trialsalmost 26 years ago
Black Women Underrepresented in Breast Cancer Trialsalmost 26 years ago
UnitedHealthcare Plan Gives Physicians Final Say on Carealmost 26 years ago
New Agents, Sequential Schedules Hold PromiseNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.